These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19147725)

  • 1. Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Sniderman A; Solhpour A
    Clin Chem; 2009 Mar; 55(3):391-3. PubMed ID: 19147725
    [No Abstract]   [Full Text] [Related]  

  • 2. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
    Clin Chem; 2009 Mar; 55(3):473-80. PubMed ID: 19147732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 4. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
    Colhoun HM; Thomason MJ; Mackness MI; Maton SM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2002 Mar; 19(3):201-11. PubMed ID: 11918622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
    Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
    Croom KF; Plosker GL
    Drugs; 2005; 65(1):137-52. PubMed ID: 15610062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins for patients with type 2 diabetes.
    Auer J; Berent R; Weber T; Eber B
    Lancet; 2004 Nov 27-Dec 3; 364(9449):1933-4. PubMed ID: 15566997
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CARDS trial: diabetic patients dealt a winning hand.
    Armani A; Toth PP
    Curr Atheroscler Rep; 2006 Sep; 8(5):429-32. PubMed ID: 16901414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins for patients with type 2 diabetes.
    Pimpinella G; Bertini Malgarini R; Martini N
    Lancet; 2004 Nov 27-Dec 3; 364(9449):1933; author reply 1933. PubMed ID: 15566999
    [No Abstract]   [Full Text] [Related]  

  • 13. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).
    Deshmukh HA; Colhoun HM; Johnson T; McKeigue PM; Betteridge DJ; Durrington PN; Fuller JH; Livingstone S; Charlton-Menys V; Neil A; Poulter N; Sever P; Shields DC; Stanton AV; Chatterjee A; Hyde C; Calle RA; DeMicco DA; Trompet S; Postmus I; Ford I; Jukema JW; Caulfield M; Hitman GA
    J Lipid Res; 2012 May; 53(5):1000-1011. PubMed ID: 22368281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study).
    Kanat M; Serin E; Tunckale A; Yildiz O; Sahin S; Bolayirli M; Arinc H; Dirican A; Karagoz Y; Altuntas Y; Celebi H; Oguz A
    J Endocrinol Invest; 2009 Nov; 32(10):852-6. PubMed ID: 19783896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of atorvastatin in cholesterol lowering.
    Farmer JA
    Curr Atheroscler Rep; 2003 Mar; 5(2):94-5. PubMed ID: 12573192
    [No Abstract]   [Full Text] [Related]  

  • 16. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets.
    Kappelle PJ; Dallinga-Thie GM; Dullaart RP;
    Biochim Biophys Acta; 2010 Jan; 1801(1):89-94. PubMed ID: 19800983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation.
    Sathyapalan T; Atkin SL; Kilpatrick ES
    Ann Clin Biochem; 2015 Jan; 52(Pt 1):180-2. PubMed ID: 24719214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
    Leiter LA; Martineau P; de Teresa E; Farsang C; Gaw A; Gensini G; Langer A;
    J Fam Pract; 2008 Oct; 57(10):661-8. PubMed ID: 18842192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.